Ifp Advisors, Inc Vertex Pharmaceuticals Inc Transaction History

Ifp Advisors, Inc

$2.42 Billion
Q2 2024

A detailed history of Ifp Advisors, Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ifp Advisors, Inc holds 2,304 shares of VRTX stock, worth $915,310. This represents 0.04% of its overall portfolio holdings.

Number of Shares

2,304

Previous 1,976 16.6%

Holding current value

$915,310

Previous $825,000 30.79%

% of portfolio

0.04%

Previous 0.04%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$392.81 - $485.53 $128,841 - $159,253	328 Added 16.6%	2,304 $1.08 Million
Q1 2024 Jul 30, 2024	SELL	$407.69 - $446.08 $64,822 - $70,926	-159 Reduced 7.45%	1,976 $825,000
Q4 2023 Jan 09, 2024	BUY	$343.0 - $410.68 $121,422 - $145,380	354 Added 19.88%	2,135 $868,000
Q3 2023 Oct 12, 2023	SELL	$338.18 - $362.46 $24,687 - $26,459	-73 Reduced 3.94%	1,781 $619,000
Q2 2023 Aug 04, 2023	BUY	$314.42 - $351.91 $90,867 - $101,701	289 Added 18.47%	1,854 $652,000
Q1 2023 Apr 18, 2023	SELL	$283.23 - $323.1 $1.51 Million - $1.73 Million	-5,339 Reduced 77.33%	1,565 $493,000
Q4 2022 Feb 07, 2023	SELL	$285.76 - $321.48 $383,775 - $431,747	-1,343 Reduced 16.28%	6,904 $1.1 Million
Q3 2022 Nov 08, 2022	BUY	$273.83 - $305.53 $194,693 - $217,231	711 Added 9.43%	8,247 $1.29 Million
Q2 2022 Sep 06, 2022	BUY	$234.96 - $292.55 $1.77 Million - $2.2 Million	7,536 New	7,536 $1.17 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $1.77 Million - $2.2 Million	-7,536 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$221.42 - $260.97 $1.41 Million - $1.67 Million	6,385 Added 554.74%	7,536 $1.97 Million
Q1 2022 Aug 08, 2022	BUY	$221.42 - $260.97 $9,078 - $10,699	41 Added 3.69%	1,151 $300,000
Q4 2021 Jan 12, 2022	SELL	$177.01 - $223.45 $9,558 - $12,066	-54 Reduced 4.64%	1,110 $245,000
Q3 2021 Oct 06, 2021	BUY	$181.39 - $202.99 $27,934 - $31,260	154 Added 15.25%	1,164 $213,000
Q2 2021 Jul 13, 2021	SELL	$187.49 - $221.1 $152,616 - $179,975	-814 Reduced 44.63%	1,010 $198,000
Q1 2021 Apr 30, 2021	SELL	$207.02 - $241.31 $87,155 - $101,591	-421 Reduced 18.75%	1,824 $400,000
Q4 2020 Jan 25, 2021	BUY	$207.01 - $276.09 $3,933 - $5,245	19 Added 0.85%	2,245 $533,000
Q3 2020 Oct 29, 2020	BUY	$255.65 - $303.1 $241,589 - $286,429	945 Added 73.77%	2,226 $613,000
Q2 2020 Aug 05, 2020	BUY	$225.48 - $295.8 $64,487 - $84,598	286 Added 28.74%	1,281 $372,000
Q1 2020 May 12, 2020	BUY	$199.77 - $247.81 $61,728 - $76,573	309 Added 45.04%	995 $223,000
Q4 2019 Jan 17, 2020	SELL	$166.71 - $223.91 $11,002 - $14,778	-66 Reduced 8.78%	686 $152,000
Q3 2019 Nov 07, 2019	BUY	$166.23 - $187.09 $49,869 - $56,127	300 Added 66.37%	752 $125,000
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $156,198 - $185,743	-954 Reduced 67.85%	452 $83,000
Q4 2018 Jan 23, 2019	SELL	$151.91 - $192.21 $34,939 - $44,208	-230 Reduced 14.06%	1,406 $232,000
Q3 2018 Oct 25, 2018	BUY	$167.73 - $192.74 $96,780 - $111,210	577 Added 54.49%	1,636 $0
Q2 2018 Aug 07, 2018	BUY	$145.72 - $169.96 $50,273 - $58,636	345 Added 48.32%	1,059 $0
Q1 2018 Jun 03, 2019	SELL	$151.6 - $177.13 $29,410 - $34,363	-194 Reduced 21.37%	714 $107,000
Q1 2018 May 09, 2018	BUY	$151.6 - $177.13 $29,410 - $34,363	194 Added 27.17%	908 $0
Q4 2017 Jan 24, 2018	SELL	$137.28 - $155.55 $20,317 - $23,021	-148 Reduced 17.17%	714 $0
Q3 2017 Oct 30, 2017	BUY	$148.13 - $162.24 $23,404 - $25,633	158 Added 22.44%	862 $131,000
Q2 2017 Jun 03, 2019	SELL	N/A	-2 Reduced 0.28%	704 $91,000
Q1 2017 Jun 03, 2019	SELL	N/A	-65 Reduced 8.43%	706 $77,000
Q4 2016 Jun 03, 2019	BUY	N/A	99 Added 14.73%	771 $57,000
Q2 2016 Jun 03, 2019	BUY	N/A	220 Added 48.67%	672 $58,000
Q1 2016 Jun 03, 2019	BUY	N/A	452	452 $83,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $102B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.

Account